DE69636997D1 - HEILUNG UND VORBEUGUNG VON DURCH NF-kappaB VERURSACHTEN ERKRANKUNGEN - Google Patents

HEILUNG UND VORBEUGUNG VON DURCH NF-kappaB VERURSACHTEN ERKRANKUNGEN

Info

Publication number
DE69636997D1
DE69636997D1 DE69636997T DE69636997T DE69636997D1 DE 69636997 D1 DE69636997 D1 DE 69636997D1 DE 69636997 T DE69636997 T DE 69636997T DE 69636997 T DE69636997 T DE 69636997T DE 69636997 D1 DE69636997 D1 DE 69636997D1
Authority
DE
Germany
Prior art keywords
prevention
diseases
kappab
healing
caused diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69636997T
Other languages
English (en)
Other versions
DE69636997T2 (de
Inventor
Ryuichi Morishita
Toshio Ogihara
Toshiko Sugimoto
Kazuhiro Maeda
Ikuo Kawamura
Toshiyuki Chiba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anges Inc
Original Assignee
Anges MG Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges MG Inc filed Critical Anges MG Inc
Application granted granted Critical
Publication of DE69636997D1 publication Critical patent/DE69636997D1/de
Publication of DE69636997T2 publication Critical patent/DE69636997T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE69636997T 1995-05-12 1996-05-10 HEILUNG UND VORBEUGUNG VON DURCH NF-kappaB VERURSACHTEN ERKRANKUNGEN Expired - Lifetime DE69636997T2 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP11499095 1995-05-12
JP11499095 1995-05-12
JP28550495 1995-11-02
JP28550495 1995-11-02
PCT/JP1996/001234 WO1996035430A1 (fr) 1995-05-12 1996-05-10 TRAITEMENT ET PREVENTION DE MALADIES ASSOCIEES A NF-λB

Publications (2)

Publication Number Publication Date
DE69636997D1 true DE69636997D1 (de) 2007-05-10
DE69636997T2 DE69636997T2 (de) 2007-07-12

Family

ID=26453615

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69636997T Expired - Lifetime DE69636997T2 (de) 1995-05-12 1996-05-10 HEILUNG UND VORBEUGUNG VON DURCH NF-kappaB VERURSACHTEN ERKRANKUNGEN

Country Status (9)

Country Link
US (4) US6262033B1 (de)
EP (1) EP0824918B1 (de)
JP (1) JP3474879B2 (de)
AT (1) ATE357922T1 (de)
DE (1) DE69636997T2 (de)
DK (1) DK0824918T3 (de)
ES (1) ES2285712T3 (de)
PT (1) PT824918E (de)
WO (1) WO1996035430A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1350514A3 (de) * 1993-10-29 2004-07-07 The Brigham And Women's Hospital, Inc. Therapeutische Verwendung von Cis-Element Ködern in vivo
ATE357922T1 (de) 1995-05-12 2007-04-15 Anges Mg Inc Heilung und vorbeugung von durch nf-kappab verursachten erkrankungen
CA2281224A1 (en) * 1997-02-15 1998-08-20 Proscript, Inc. Treatment of infarcts through inhibition of nf-kappab
US6586661B1 (en) 1997-06-12 2003-07-01 North Carolina State University Regulation of quinolate phosphoribosyl transferase expression by transformation with a tobacco quinolate phosphoribosyl transferase nucleic acid
EP1008352A4 (de) * 1997-07-04 2005-03-16 Fujisawa Pharmaceutical Co Gehirnschützender wirkstoff
EP1018514B1 (de) 1998-07-22 2004-05-12 Daiichi Suntory Pharma Co., Ltd. Nf-kappa b inhibitoren, die indanderivate als aktiven bestandteil enthalten
AU5329599A (en) 1998-07-30 2000-02-21 University Of South Florida Method for the modulation of function of transcription factors
DE19926216A1 (de) * 1999-06-09 2001-02-22 Metallgesellschaft Ag Verfahren zur Herstellung von Bariumsulfat, Bariumsulfat und Verwendung des Bariumsulfats
HUP0104841A3 (en) * 1999-09-17 2002-07-29 Daiichi Suntory Pharma Co Ltd Medicaments containing benzoquinone- or condensed pyrimidine derivatives as active ingredient for treating of myocarditis, dilated cardiomyopathy and cardiac insufficiency
EP1313868B1 (de) 2000-08-30 2006-07-19 North Carolina State University Transgene pflanzen, die molekulare decoys enthalten, die den proteininhalt ändern
JP2002065278A (ja) * 2000-08-31 2002-03-05 Anges Mg Inc Ｈｖｊの融合タンパク質を含有する遺伝子移入ビヒクル
EP1368467B1 (de) * 2000-11-07 2007-04-25 North Carolina State University Putrescin-n-methyltransferasepromotor
WO2002069995A2 (en) * 2001-02-16 2002-09-12 Medical College Of Georgia Research Institute, Inc. Use of trail and antiprogestins for treating cancer
DE60225899T2 (de) * 2001-02-20 2009-04-09 AnGes MG Inc., Ibaraki-shi TOPISCHE ANWENDUNG EINES NF-kB DECOYS ZUR BEHANDLUNG ATOPISCHER DERMATITIS
NZ530238A (en) * 2001-06-08 2004-08-27 Vector Tobacco Ltd Modifying nicotine and nitrosamine levels in tobacco
US20060157072A1 (en) * 2001-06-08 2006-07-20 Anthony Albino Method of reducing the harmful effects of orally or transdermally delivered nicotine
US20050175539A1 (en) * 2001-11-22 2005-08-11 Ryuichi Morishita Compositions inhibiting rejection in organ transplantation and method of using the same
WO2003063911A1 (fr) * 2002-02-01 2003-08-07 Anges Mg, Inc. Compositions pharmaceutiques contenant un leurre et procede d'utilisation
JPWO2003082331A1 (ja) * 2002-03-29 2005-07-28 アンジェスＭｇ株式会社 脳疾患および障害を処置および予防するためのデコイ組成物
JP2005522201A (ja) * 2002-04-09 2005-07-28 ベクター、タバコ、リミテッド ニコチンおよびニトロソアミンを減少させたタバコ
US20070014840A1 (en) 2002-04-26 2007-01-18 In-Kyu Lee Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription
CN1306964C (zh) * 2002-05-29 2007-03-28 安琪士摩奇株式会社 治疗和预防炎症性疾病的诱饵组合物
JPWO2004002465A1 (ja) * 2002-06-26 2005-10-27 株式会社シグナル・クリエーション ＮＦ−κＢ阻害剤を含む医薬組成物
CA2500367A1 (en) * 2002-09-20 2004-04-01 Anges Mg, Inc. Agents for protection from neointimal formation in grafts comprising an nfkb dekoy
CA2525017A1 (en) * 2003-05-09 2004-12-23 Anges Mg, Inc. Needleless syringe having medical agent accommodated therein
AU2003252493A1 (en) * 2003-07-09 2005-01-28 Anges Mg, Inc. Pharmaceutical composition containing decoy and method of using the same
US6884443B2 (en) 2003-08-07 2005-04-26 General Mills, Inc. Compositions and methods relating to freezer-to-oven doughs
WO2005056020A2 (en) * 2003-12-02 2005-06-23 Corgentech, Inc. Nf-kb oligonucleotide decoy molecules
US8034619B2 (en) * 2003-12-19 2011-10-11 University Of Cincinnati Polyamides for nucleic acid delivery
SE0400399D0 (sv) * 2004-02-20 2004-02-20 Index Pharmaceuticals Ab Methods and compositions for the treatment or prevention of secondary ischemic injury
US7482158B2 (en) * 2004-07-01 2009-01-27 Mathison Brian H Composite polynucleic acid therapeutics
CA2583413A1 (en) * 2004-09-21 2006-03-30 Anesiva, Inc. Delivery of polynucleotides
WO2006043722A1 (ja) * 2004-10-22 2006-04-27 Anges Mg, Inc. キメラ（ダブル）デコイ
US20080312145A1 (en) * 2004-12-16 2008-12-18 Anges Mg, Inc. Agent for Regulating Bone Formation
US7585848B2 (en) 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
WO2006075776A1 (ja) * 2005-01-13 2006-07-20 Anges Mg, Inc. 慢性閉塞性肺疾患(COPD)、嚢胞性線維症(Cystic Fibrosis)または肺高血圧症(pulmonary hypertension)治療剤
US20090214630A1 (en) * 2005-05-10 2009-08-27 Warren Strober Compositions and Methods for the Treatment of Inflammatory Bowel Disease Utilizing NF-KappaB Decoy Polynucleotides
US20060258604A1 (en) * 2005-05-10 2006-11-16 Warren Strober Compositions and methods for the treatment of inflammatory bowel disease utilizing NF-kappaB decoy polynucleotides
CA2614295A1 (en) 2005-06-06 2006-12-14 Anges Mg, Inc. Transcription factor decoy
JPWO2007072909A1 (ja) 2005-12-22 2009-06-04 アンジェスＭｇ株式会社 新規オリゴヌクレオチド及びそれから成るＮＦ−κＢデコイ
US8501478B2 (en) * 2006-06-15 2013-08-06 University Of Cincinnati Trehalose click polymers for delivery of biologically active molecules
JP4602298B2 (ja) * 2006-08-31 2010-12-22 ホソカワミクロン株式会社 医薬製剤
JP5384120B2 (ja) 2007-02-16 2014-01-08 アンジェスＭｇ株式会社 歯周病、及び外科手術による歯槽骨欠損の治療剤
JP5312747B2 (ja) * 2007-03-01 2013-10-09 ジェノミディア株式会社 Ｈｖｊエンベロープによるタンパク質の導入方法
PL2158316T3 (pl) 2007-05-11 2015-10-30 Adynxx Inc Ekspresja genowa oraz ból
KR20100127300A (ko) * 2008-03-28 2010-12-03 안게스 엠지 인코포레이티드 전사 인자 디코이를 유효 성분으로 하는 외용제 조성물
JP5057587B2 (ja) * 2009-05-20 2012-10-24 アンジェスＭｇ株式会社 デコイを含む薬学的組成物およびその使用方法
JPWO2013024763A1 (ja) 2011-08-12 2015-03-05 独立行政法人理化学研究所 核酸アプタマーの作製方法
EP2846839B1 (de) 2012-05-10 2019-02-20 Adynxx, Inc. Formulierungen zur abgabe von wirkstoffen
CA2957250A1 (en) 2014-08-15 2016-02-18 Adynxx, Inc. Oligonucleotide decoys for the treatment of pain
JPWO2017068790A1 (ja) * 2015-10-23 2018-08-09 レナセラピューティクス株式会社 核酸複合体

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410516B1 (en) * 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
AU2140592A (en) 1991-05-17 1992-12-30 Chiron Corporation Inhibitor of nf-kappa b transcriptional activator and uses thereof
CA2105595A1 (en) * 1992-09-23 1994-03-24 Ramaswamy Narayanan Antisense polynucleotides
JPH07170998A (ja) * 1993-09-07 1995-07-11 Yissum Res Dev Co Of Hebrew Univ Of Jerusalem ＮＦ−κＢの調節方法
CA2131587A1 (en) 1993-09-07 1995-03-08 Yinon Ben-Neriah Method for regulation of nf-kb
JPH07114990A (ja) 1993-10-14 1995-05-02 Plus Kk ハロゲンランプ調光装置
EP1350514A3 (de) * 1993-10-29 2004-07-07 The Brigham And Women's Hospital, Inc. Therapeutische Verwendung von Cis-Element Ködern in vivo
US6399376B1 (en) * 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
JPH07285504A (ja) 1994-04-14 1995-10-31 Asano Seiki Kk 粉粒体充填装置
ATE357922T1 (de) 1995-05-12 2007-04-15 Anges Mg Inc Heilung und vorbeugung von durch nf-kappab verursachten erkrankungen

Also Published As

Publication number Publication date
PT824918E (pt) 2007-06-22
US20040162250A1 (en) 2004-08-19
DK0824918T3 (da) 2007-06-04
US7871983B2 (en) 2011-01-18
ES2285712T3 (es) 2007-11-16
US20060116344A1 (en) 2006-06-01
JP3474879B2 (ja) 2003-12-08
DE69636997T2 (de) 2007-07-12
EP0824918A1 (de) 1998-02-25
ATE357922T1 (de) 2007-04-15
EP0824918A4 (de) 2004-11-17
WO1996035430A1 (fr) 1996-11-14
US20020098162A1 (en) 2002-07-25
US6262033B1 (en) 2001-07-17
EP0824918B1 (de) 2007-03-28

Similar Documents

Publication Publication Date Title
DE69636997D1 (de) HEILUNG UND VORBEUGUNG VON DURCH NF-kappaB VERURSACHTEN ERKRANKUNGEN
DE122009000012I1 (de) Substituierte pyrazolyl-benzolsulfonamide zur behandlung von entzundungen.
DE69615510D1 (de) Passivierung von organischen Vorrichtungen
DE69630162D1 (de) Passivierung von organischen Vorrichtungen
DE69319551D1 (de) Indolin Verbindungen zur Behandlung von Dysurien
DE69739583D1 (de) Topische zusammensetzungen enthaltend als therapeutisch aktiven wirkstoff ein monoglycerid zur behandlung von schleimhautinfektionen
ATE288893T1 (de) Polymorphe form von atorvastatin-calcium
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
DE69831134D1 (de) Behandlung von wasser
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
DE69318835D1 (de) Behandlung einer refluxstörung durch injektion von mikropartikeln
DE69427869D1 (de) Botulinumtoxine zur behandlung von hyperhydrosis
DE69319270D1 (de) Verfahren zur Behandlung von organischen Schlämmen
ATE235481T1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
DE69227883D1 (de) Riechstoffmikrokapseln zur Behandlung von Wäsche
DE69603089D1 (de) Zusammensetzung zur behandlung von mauerwerk
PT705100E (pt) Guanidinas substituidas terapeuticas
DE69821667D1 (de) Kardioverter zur Behandlung von Vorhofflattern
FI932695A0 (fi) Angiotensin I kymas-inhibitorer inklusive humant hjaertkymas
ATE231837T1 (de) Hydroxamsäure- und carbonsäurederivate mit mmp und tnf hemmender wirkung
ATE161143T1 (de) Neue verwendung von hexaflumuron und verwandte verbindungen als termitizide
DE69316203D1 (de) Elektrochemische behandlung von oberflächen
DE59305662D1 (de) Synergistische mittel zur bekämpfung von insekten und akarina
DE69429101D1 (de) Verbindungen und zusammensetzungen zur behandlung von allergien und entzündungen
DE69120387D1 (de) Danazol enthaltende Arzneimittel zur Behandlung von Endometriosis

Legal Events

Date Code Title Description
8364 No opposition during term of opposition